<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05122637</url>
  </required_header>
  <id_info>
    <org_study_id>DEV-0213</org_study_id>
    <nct_id>NCT05122637</nct_id>
  </id_info>
  <brief_title>Feasibility Study of RapidPulseTM Aspiration System as Frontline Approach for Stroke Patients</brief_title>
  <acronym>RapidPulseFS</acronym>
  <official_title>Feasibility Study of RapidPulseTM Aspiration System as Frontline Approach for Patients With Acute Ischemic Stroke Due to Large Vessel Occlusions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RapidPulse, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RapidPulse, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Feasibility Study to evaluate the initial safety and performance of the RapidPulseTM&#xD;
      Aspiration System in the treatment of patients with Acute Ischemic Stroke (AIS) due to Large&#xD;
      Vessel Occlusion (LVO).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the initial safety and performance of the RapidPulse&#xD;
      Inc. RapidPulseTM Aspiration System as frontline approach for use in the treatment of&#xD;
      patients with Acute Ischemic Stroke (AIS) due to Large Vessel Occlusion (LVO). This is a&#xD;
      prospective, multi-center, open label study comparing the safety and performance of the&#xD;
      RapidPulseTM Aspiration System with non-randomized retrospective controls who otherwise meet&#xD;
      the same study inclusion/exclusion criteria. The study will enroll a maximum of 100&#xD;
      participants in the Treatment Arm and a maximum of 200 participants in the Control Arm at in&#xD;
      up to 10 centers in Europe and/or Latin America. Subjects data will be collected through&#xD;
      hospitalization with a 3 months post-procedure study visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>First Pass Reperfusion Effect (FPE)</measure>
    <time_frame>Intra-procedural</time_frame>
    <description>Defined by modified Thrombolysis In Cerebral Infarction scale (mTICI 2c-3) flow in the target vessel</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frontline technical success</measure>
    <time_frame>Intra-procedural</time_frame>
    <description>Defined by mTICI ≥ 2b after the last pass with Study Device with no rescue therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Good functional outcome measured by Modified Rankin Scale score of 0 - 2 at 90 days post index procedure</measure>
    <time_frame>90 days</time_frame>
    <description>The Modified Rankin Scale (mRS) measures neurological disability or dependence for stroke patients on a scale of 0 (no symptoms) to 6 (deceased)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Symptomatic intracranial hemorrhage (sICH) at 24 hours post-procedure</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality rate</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RapidPulseTM Aspiration System with commercially available Medtronic React 71 aspiration catheter and commercially available aspiration pump as frontline approach thrombectomy technique.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment with commercially available aspiration catheter with commercially available aspiration pump as frontline approach thrombectomy technique.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RapidPulseTM Aspiration System</intervention_name>
    <description>The RapidPulseTM Aspiration System with Medtronic React 71 aspiration catheter and a commercially available pump.</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard of Care Aspiration Thrombectomy System</intervention_name>
    <description>Commercially available aspiration catheter with commercially available aspiration pump</description>
    <arm_group_label>Control Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Clinical diagnosis of acute ischemic stroke with NIH Stroke Scale (NIHSS) score ≥ 6&#xD;
             with symptom onset (or last seen normal) up to 24 hours&#xD;
&#xD;
          -  Large vessel occlusion in the intracranial internal carotid artery (ICA), middle&#xD;
             cerebral artery (MCA) M1 or M2 segments, basilar or vertebral artery&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of hemorrhage&#xD;
&#xD;
          -  Significant mass effect and/or midline shift&#xD;
&#xD;
          -  Vessel tortuosity too difficult to allow endovascular access per investigator judgment&#xD;
&#xD;
          -  Severe or fatal co-morbidities&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raul G Nogueira, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Marcus Stroke &amp; Neuroscience Center, Grady Memorial Hospital; Emory University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cynthia Yang</last_name>
    <phone>9498367402</phone>
    <email>cyang@rapidpulsemed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Istanbul Aydin University</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <contact>
      <last_name>Serdar Geyik, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 3, 2021</study_first_submitted>
  <study_first_submitted_qc>November 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Large vessel occlusion</keyword>
  <keyword>Mechanical thrombectomy</keyword>
  <keyword>Neurovascular intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

